Ontuxizumab

Ontuxizumab
Monoclonal antibody
Type Whole antibody
Source Chimeric/humanized hybrid (mouse/human)
Target TEM1
Clinical data
ATC code none
Identifiers
CAS Number 946415-62-9
ChemSpider none
Chemical and physical data
Formula C6532H10050N1726O2054S44
Molar mass 147.0 kg/mol

Ontuxizumab[1] is a monoclonal antibody designed for the treatment of cancer. It binds to endosialin (TEM1).[2]

This drug was developed by Morphotek.

References

  1. World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109" (PDF). WHO Drug Information. 27 (2).
  2. Kiyohara, E; Donovan, N; Takeshima, L; Huang, S; Wilmott, J. S.; Scolyer, R. A.; Jones, P; Somers, E. B.; O'Shannessy, D. J.; Hoon, D. S. (2015). "Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications". Cancer Microenvironment. 8 (2): 111–8. doi:10.1007/s12307-015-0168-8. PMC 4542822Freely accessible. PMID 26085332.


This article is issued from Wikipedia - version of the 4/19/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.